Empowered Patient Podcast

Shai Shen-Orr, the Co-Founder and Chief Scientist of CytoReason, is developing computational disease models powered by AI to improve the probability of success in phase 2 clinical trials. Their goal is to more precisely develop drugs using AI to analyze large amounts of biological and clinical data and overcome the challenges of the complexity and uncertainty in medical information. Working with large pharmaceutical companies, CytoReason is supporting companies in their drug development efforts and helping them choose the right drug target and patient populations to study.   Shai explains, "There are many challenges. I would say that CytoReason right now isn't tackling images. And there are certainly companies in the field that have been doing this. We've been focused more on the molecular side of the data, the genes, the proteins, the cells, the genetics. But the challenge is that when you work in this field and try to do AI in biology, it's very difficult for us to know the ground truth. We don't know when